Neurobiological and Genomic Predictors of Relapse in Depression

Plain-language summary

This study investigates neurobiological and genomic markers that might predict relapse (the return of symptoms) in depression (major depressive disorder). Participants are treated with antidepressant medications; the study enrolls outpatients diagnosed with major depressive disorder per DSM-5-TR who have been drug-free for at least one week. It is a study with no assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Mehmet Kemal Arikan

Intervention

Antidepressant Medications

Start date

1/1/2025

Estimated completion

2/1/2027

Countries

Turkey (Türkiye)

Related genes

Locations

• Istanbul, Turkey (Türkiye)

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Outpatients
* For patients, satisfying Major Depressive Disorder for Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR)
* Drug-free for at least 1-week

Exclusion Criteria:

* Any neurological and psychiatric comorbid conditions
* Hearing loss
* Physical diseases